Threshold Pharmaceuticals (THLD) is a developmental biopharmaceutical company focused on cancer therapeutics that target tumor hypoxia. Hypoxia (lack of oxygen) is present in almost all solid tumor cancers and is also associated with certain blood cancers. THLD's most developed drug is TH-302, which is currently being evaluated in multiple clinical studies for the treatment of soft tissue sarcoma, pancreatic cancer and a variety of other solid and hematologic tumors. TH-302 is activated under conditions of severe tumor hypoxia with the hope of being more effective in destroying tumors while minimizing toxicity to healthy tissue. THLD has patent protection for TH-302 through 2029.
Only subscribers can access this article, which is part of the PRO research library covering 3,773 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: